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RESEARCH
Liraglutide improves the beta-cell 
function without increasing insulin secretion 
during a mixed meal in patients, who exhibit 
well-controlled type 2 diabetes and coronary 
artery disease
Christian Anholm1,2* , Preman Kumarathurai2, Anders Jürs2, Lene Rørholm Pedersen2, 
Olav Wendelboe Nielsen2, Ole Peter Kristiansen2, Mogens Fenger3, Jens Juul Holst4, Sten Madsbad5, 
Ahmad Sajadieh2 and Steen Bendix Haugaard1,6
Abstract 
Background: Hyperinsulinemia aggravates insulin resistance and cardio-vascular disease. How the insulinotropic 
glucagon-like peptide-1 receptor agonist liraglutide in a physiologic post-prandial setting may act on pancreatic 
alpha and beta-cell function in patients with coronary artery disease (CAD) and type 2 diabetes (T2DM) is less clear.
Methods: Insulin resistant patients with established CAD and newly diagnosed well-controlled T2DM were recruited 
to a placebo-controlled, cross-over trial with two treatment periods of 12 weeks and a 2 weeks wash-out period 
before and in-between. Treatment was liraglutide or placebo titrated from 0.6 mg q.d. to 1.8 mg q.d. within 4 weeks 
and metformin titrated from 500 mg b.i.d to 1000 mg b.i.d. within 4 weeks. Before and after intervention in both 
12 weeks periods insulin, C-peptide, glucose, and glucagon were measured during a meal test. Beta-cell function 
derived from the oral glucose tolerance setting was calculated as changes in insulin secretion per unit changes in 
glucose concentration  (Btotal) and whole-body insulin resistance using  ISIcomposite.
Results: Liraglutide increased the disposition index  [Btotal × ISIcomposite, by 40% (n = 24, p < 0.001)] compared to 
placebo. Post-prandial insulin and glucose was reduced by metformin in combination with liraglutide and differed, 
but not significantly different from placebo, moreover, glucagon concentration was unaffected. Additionally, insulin 
clearance tended to increase during liraglutide therapy (n = 26, p = 0.06).
Conclusions: The insulinotropic drug liraglutide may without increasing the insulin concentration reduce postpran-
dial glucose but not glucagon excursions and improve beta-cell function in newly diagnosed and well-controlled 
T2DM.
Trial registration Clinicaltrials.gov ID: NCT01595789
Keywords: GLP1-receptor agonist, Diabetes mellitus type 2, Beta-cell function, Insulin sensitivity, Meal test, Insulin 
clearance, Glucagon
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Background
The hyperglycemia in type 2 diabetes mellitus (T2DM) 
results from an imbalance between insulin secretion 
and insulin sensitivity [1] with impaired insulin action 
and an insufficient and delayed insulin response dur-
ing meals as well as an inappropriate glucagon secre-
tion [2]. Fasting as well as postprandial glucagon 
secretion increase progressively through the spectrum 
of impaired glucose tolerance to manifest T2DM [3]. 
The hyperglucagonemia is associated with hepatic 
insulin resistance [4] and an increased hepatic glu-
cose production [5]. Elevated levels of non-esterified 
fatty acids (NEFA) resulting from adipose tissue insu-
lin resistance may play a role in the development of 
peripheral as well as hepatic insulin resistance and 
may also impair beta-cell function in T2DM and in 
obese prediabetic individuals [6].
Metformin, which is recommended as first line ther-
apy in patients with T2DM [7], has beneficial effects 
on HbA1c, body weight, cardiovascular mortality [7, 8] 
and insulin sensitivity [9]. However, metformin treat-
ment has no effect on glucagon levels [10], whereas 
GLP-1 receptor agonists (GLP-1RA) have been sug-
gested to inhibit glucagon secretion from alpha-cells 
[11, 12]. Furthermore, therapy with GLP1-RA is asso-
ciated with a potentiation of glucose induced insu-
lin secretion and a modest weight loss [13] and as a 
result it effectively reduces hyperglycemia in patients 
with T2DM [14]. This antihyperglycemic action of the 
GLP1-RA liraglutide is well-established in patients 
with longstanding not well-controlled diabetes [15–
19]. The effect of GLP-1 receptor agonist on insulin 
sensitivity is still discussed [20–22], and its effect on 
insulin clearance is sparsely examined [23]. Newly 
diagnosed T2DM in patients with coronary artery dis-
ease (CAD) is associated with excess mortality [24]. 
Accordingly, it would be of interest how liraglutide 
may improve postprandial glycaemia and insulinemia 
in a population of newly diagnosed well-controlled 
T2DM subjects with CAD, particularly considering 
that liraglutide is insulinotropic.
The aims of the present study, therefore, were to 
evaluate effects of the GLP-1 RA liraglutide in combi-
nation with metformin on indices of alpha- and beta-
cell function, insulin sensitivity and insulin clearance. 
This was evaluated using a mixed meal test in obese 
patients with newly diagnosed, well-controlled T2DM 
and high cardiovascular risk, a population in which 
efficacy of antidiabetic medication is essential and 
where several recent guidelines recommend GLP-1 
RA, e.g. liraglutide as drug number 2 after metformin 
[7, 25].
Methods
Subjects
The inclusion criteria were stable coronary artery dis-
ease (CAD), body mass index (BMI) ≥ 25 kg/m2, age ≥ 18 
and ≤ 85  years, and newly diagnosed (< 2  years) T2DM 
according to the criteria defined by the American Diabe-
tes Association [26]. To be included, the patients were to 
be treated with diet, metformin or sulfonylurea alone or 
in combinations. All oral antidiabetic medications were 
stopped 2 weeks before baseline visit (Table 1). Exclusion 
criteria were, amongst others, previous treatment with 
a GLP-1RA or dipeptidyl peptidase-4 inhibitor. A com-
prehensive list of the exclusion criteria can be found else-
where [27].
Design
The study was an investigator-initiated, double-blind, 
randomized, placebo-controlled, cross-over trial. Details 
of the design, participants and intervention have been 
described previously [27].
Patients meeting the inclusion criteria were included 
consecutively and study drugs in subject boxes were 
sequentially numbered with a unique code and rand-
omized by computer in a 1:1 randomization ratio by 
Novo Nordisk A/S and allocation sequence was con-
cealed until all participants had completed the study [27]. 
Enrollment and assignment of participants were done at 
Department of Cardiology, Copenhagen University Hos-
pital, Bispebjerg, Denmark. Patients were recruited from 
May 2012 to October 2014.
Intervention
Liraglutide and metformin versus placebo and metformin 
in 12 plus 12 weeks with a 2-week wash-out period. The 
study period for each patient was 26 weeks and consisted 
of 4 major visits (at weeks 0, 12, 14 and 26); the wash-
out was between weeks 12 and 14. Liraglutide dose was 
1.8  mg once daily subcutaneously (titrated from 0.6  mg 
to 1.8 mg once daily within 4 weeks) and metformin 1 g 
twice daily orally (titrated from 500 mg twice daily to 1 g 
twice daily in 4 weeks) [27]. The last injection of liraglu-
tide was in the morning on test days. Data collection was 
carried out in Department of Cardiology, Copenhagen 
University Hospital, Bispebjerg, Denmark.
Endpoints
Beta-cell function (as measured by disposition index), 
insulin sensitivity, insulin clearance and responses of glu-
cose, insulin, C-peptide, glucagon and NEFA during a 2-h 
mixed meal tolerance test, respectively. Treatment effects 
were evaluated by comparing results from the visits at 
initiation and end of each treatment period.
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Mixed meal test
A 375-g solid meal consisting of 60-g (46 E%) carbohy-
drates, 38-g (28 E%) protein and 16-g (26 E%) fat, equiva-
lent to 550 kcal was consumed after an overnight fasting 
period of 10 h. Baseline blood samples were obtained at 
10, 5 and 1 min before and 30, 60, 90 and 120 min after 
initiation of the test meal, which was to be finished 
within 15 min.
Assay
Glucose measurements were carried out using an Accu-
Chek Inform II meter (Roche, Swiss). Coefficient of vari-
ance (CV) was ≤ 3.3% for glucose levels > 4.2  mmol/l. 
Plasma insulin and C-peptide concentrations (pmol/l) 
were determined by the enzyme-linked immunosorb-
ent assay (ELISA) (Siemens Healthcare Diagnostics, 
LA, California, USA), for insulin with an intra-assay CV 
of 3.3–5.5% and an inter-assay CV of 4.1–7.3% and for 
C-peptide with an intra-assay CV of 1.7–2.3% and an 
inter-assay CV of 2.9–4.8%. Plasma NEFA (mmol/l) was 
measured by an enzymatic test (Wako Chemicals, Neuss, 
Germany) with a median intra-assay CV of 1.5% and a 
median inter-assay CV of 7.5%. Glucagon concentrations 
in plasma were measured after extraction of plasma with 
70% ethanol (vol./vol., final concentration). The antibody 
employed (code no. 4305) is directed against the C-termi-
nus of the glucagon molecule and therefore mainly meas-
ures glucagon of pancreatic origin [28]. Standards were 
human glucagon and tracer was monoiodinated human 
glucagon (both gifts from Novo Nordisk, Bagsværd, Den-
mark). Sensitivity and detection limit is below 1 pmol/l, 
intra-assay CV below 6% at 20–30 pmol/l, and recovery 
of standard, added to plasma before extraction, about 
100% when corrected for losses inherent in the plasma 
extraction procedure [29].
Calculations
The composite measure of whole body insulin sensitivity 
 (ISIComposite) [30] and the homeostasis model assessment 
of insulin resistance (HOMA-IR) [31] were determined 
as follows:
Table 1 Baseline characteristics of the study population, in median (IQR)
a Mean (SD)
b Anti diabetic treatment
Variable Units Median 25th Pctl 75th Pctl n
BMI kg/m2 30.2 27.9 34.1 39
Age years 64.0 58.0 68.0 39
Weight kg 93.0 85.0 108.0 39
HbA1ca mmol/mol 47 (6) 39
Fasting glucose mmol/l 5.3 5.0 6.2 39
Fasting  glucagona pmol/l 5.3 (3.5)
Fasting C-peptide pmol/l 1474 1006 1978 39
Fasting insulin pmol/l 110 67 178 38
Fasting NEFA mmol/l 0.392 0.298 0.455 39
AUC glucose mmol/l × 120min 821.3 750.5 915.5 39
AUC insulin pmol/l × 120min 33,173 25,350 45,625 38
AUC ISR pmol/kg 969.5 811.1 1263.6 38
AUC NEFA mmol/l × 120min 28.9 22.5 36.1 39
HOMA-IR 4.43 2.24 6.93 38
ISIComposite l
2/mg/microU 3.2 2.03 4.62 38
B-total 2.54 1.61 3.2 38
MCRikg l/kg/min 0.029 0.023 0.036 37
MCRitotal l/min 2.548 2.219 3.164 37
DI 8.06 5.71 12.91 37
IDRbasal pmol/kg/min 3.09 1.94 4.02 37
HEXi 0.30 0.22 0.36 37
Pre-study  ADTb n (%)
Diet and lifestyle intervention 24 (62)
Metformin 15 (38)
Sulfonylurea 1 (3)
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in which FPI is fasting plasma insulin (μU/ml), I¯ is mean 
plasma insulin, FPG is fasting plasma glucose (mg/dl) 
and G¯ is mean plasma glucose during meal test.
Prehepatic insulin secretion rates (ISR) (pmol/kg/min) 
were calculated from plasma C-peptide concentrations 
using the ISEC (Insulin SECretion) computer program [32]. 
This method is based upon the assumptions that C-peptide 
is not cleared by the liver and is co-secreted with insulin 
in equimolar amounts from the pancreas. The beta-cell 
response to changes in glucose during a meal test expresses 
the efficacy by which changes in plasma glucose concentra-
tions stimulate insulin secretion. This relationship between 
changes in plasma glucose concentrations and ISR during 
the meal test was evaluated by cross-correlation analysis, 
and the slope of the regression lines  (BTotal) is a measure of 
the change in insulin secretion per unit change in glucose 
concentration, i.e. beta cell sensitivity to glucose or beta-
cell responsiveness. Beta-cell function was defined as the 
product of beta-cell responsiveness and insulin sensitivity, 
i.e. the disposition index  (Di) [33], i.e. assuming a hyper-
bolic association between beta-cell responsiveness and 
insulin sensitivity
We tested for the hyperbolic law in the basal state and 
found a  R2 = 0.81 suggesting that the disposition index 
may be valid to use in the present study.
The trapezoidal rule [34] was used to calculate the area 
under the curve (AUC) for ISR, insulin, glucose and NEFA 
concentrations. The integer of ISR (AUC − ISR0–120  min) 
represents the total amount of insulin secreted through-
out the meal test while the integer of insulin concentration 
profiles during the meal test (AUC − insulin0–120 min) repre-
sents both insulin secretion and insulin clearance. Thus, the 
ratio of these integers adjusted for total body mass reflects 
insulin clearance (MCRi):
Plasma insulin levels are at steady-state in the basal 
period, therefore the posthepatic insulin delivery rate 
 (IDRBasal) can be calculated as [35]:
The ratio of the  IDRBasal to the  ISRBasal is the fraction of 
insulin not extracted by the liver, therefore the hepatic 
extraction of insulin (HEXi) is calculated as [35]:
ISIcomposite =
10, 000√
(FPG × FPI)×
(
G¯ × I¯
)
HOMA−IR =
(FPG × FPI)
405
Di = Btotal × ISIcomposite
MCRi =
AUC − ISR0−120min
AUC − Insulin0−120min
× Total bodymass
IDRBasal = insulinBasal ×MCRi
To evaluate the efficacy of insulin to suppress NEFA 
production [36] we divided ∆AUC − NEFA0–120  min by 
∆AUC − insulin0–120 min, (denoted  NEFAins).
Statistical analysis
Data are reported as median (IQR) or mean (SD). Stu-
dents’ paired t-test was used for normally distributed data 
when comparing groups. In non-normally distributed 
data, Wilcoxon’s Signed Rank test was used. A two-sided 
value of p < 0.05 was considered statistically significant. 
Comprehensive details on the power calculation are pub-
lished elsewhere [27]. Statistical analyses were performed 
with SAS 9.4 (SAS Institute Inc., Cary, North Carolina, 
USA). The study was approved by the Regional Commit-
tee on Biomedical Research Ethics of the Capital Region 
of Denmark and was carried out in accordance with the 
International Conference on Harmonization—Good 
Clinical Practice standards and informed consent was 
obtained from all participants. The study protocol was 
registered at Clinicaltrials.gov with ID: NCT01595789.
Results
Participants
Of the 41 patients randomized, two patients declined to 
participate before first visit and nine patients discontin-
ued the study (Fig.  1). Twenty-eight patients completed 
all study visits. Two patients treated with placebo in the 
first period could not attend visit 3 therefore data from 
visit 2 were carried forward and used as baseline for the 
second period. Thus, thirty participants were included 
in the paired analyses. Eliminating data from the two 
patients did not influence the main results. Baseline char-
acteristics are found in Table  1. Calculations of indices 
were limited by missing values in a few patients, thereby 
leading to patients < 30 (Tables  2, 3). At baseline mean 
HbA1c was 47 [6] mmol/mol.
Alpha‑cell function
Baseline fasting p-glucagon was 5.3 (3.5) pmol/l. Both 
placebo and liraglutide treatment increased fasting gluca-
gon levels to 7.5 (3.8) pmol/l (p < 0.001) and 6.8 (3.1) 
pmol/l (p < 0.002), respectively, but with no significant 
difference between periods (p < 0.7). AUC glucagon was not 
significantly changed by placebo treatment [1138 (663) 
to 1283 (637) pmol/l × 120min (p = 0.07)], and neither 
did liraglutide treatment affect AUC glucagon [992 (516) 
to 995 (417) pmol/l × 120min (p = 0.64)], and no differ-
ence between treatments was observed (p < 0.4). AUC 
insulin/glucagon was reduced by placebo (p = 0.01) but not 
HEXi = 1−
IDRBasal
ISRBasal
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by liraglutide treatment (p < 0.06) and with no difference 
between treatment periods (p = 0.09) (Fig. 2).
Insulin sensitivity
ISI-composite  (ISIcomp) was increased in both treatment 
periods: placebo; 0.73 (− 0.05 to 2.31)  l2/mg/microU 
(p < 0.0005) and liraglutide; 1.68 (0.57 to 3.34)  l2/mg/
microU (p < 0.0001), with no significant differences 
between treatments (p = 0.14). HOMA-IR was reduced 
significantly in both placebo and the liraglutide period 
but with no differences between treatments (Table 2).
Beta‑cell function and plasma glucose
AUC glucose was reduced in both placebo and liraglu-
tide periods by − 76 (− 144 to − 29) mmol/l × 120min 
and − 106 (− 213 to − 41) mmol/l × 120min, p = 0.0003 
vs. p < 0.0001, respectively, with no difference between 
treatments (Table  3 and Fig.  2). Insulin and C-pep-
tide responses are depicted in Fig.  2. Analysis of AUC’s 
showed significant reductions of AUC insulin in both pla-
cebo and liraglutide periods with no significant difference 
between treatments (p < 0.46) (Table 3). Additionally, the 
AUC insulin/glucose ratio was not increased by liraglu-
tide treatment: − 50 (312) pmol/mmol (p = 0.4).
Basal insulin delivery rates  (IDRbasal) were not affected 
by either treatment (Table  2). AUC ISR was significantly 
reduced only in the placebo period, with no additional 
change observed with liraglutide treatment (Table  3). 
Paired analysis (n = 25) did not reveal significant differ-
ences in ISR between placebo and liraglutide treatment 
(Table  3). Beta-cell responsiveness  (Btotal) did not dif-
fer between treatments (Table 2). Disposition index (DI) 
was improved in the liraglutide period; 6.0 (2.78 to 9.23), 
p < 0.0001, whereas placebo treatment did not affect DI 
significantly. Paired analysis revealed an effect of liraglu-
tide therapy of 3.35 (− 0.51 to 9.29), p = 0.0005, improv-
ing baseline value by 40% (Table 2) towards a less diabetic 
state (Fig. 3). Of importance we observed a strong base-
line hyperbolic association between  ISIcomp and  Btotal of 
 R2 = 0.81, which comply with the data that was obtained 
in the original method study on this relationship using 
intravenous glucose defining the beta-cell function [37].
Insulin clearance
Baseline fasting insulin was inversely correlated to 
 MCRikg  (R2 = 0.58, p < 0.0001),  MCRitotal  (R2 = 0.33, 
p = 0.001) and HEXi  (R2 = 0.31, p < 0.002). In the placebo 
period  MCRikg was numerically but non-significantly 
increased but the combination of liraglutide and met-
formin increased  MCRikg significantly by 3.56 (0.29 to 
7.02) × 10−3 L/kg/min (p = 0.005) with a borderline dif-
ference between groups (p = 0.06) (Table  2). Improve-
ment in  ISIcomp was associated with reduction in  MCRikg 
 (R2 = 0.21, p = 0.02) and  MCRitotal  (R2 = 0.24, p = 0.01). 
There were no associations with HOMA-IR. Baseline 
HEXi was reduced as compared to normoglycemic sub-
jects who usually clear app. 50% or more during the first 
pass of the liver [38]. These patients exhibit a HEXi of 
only 29% (21 to 36%) and liraglutide therapy had no effect 
on HEXi.
Fig. 1 Screening, randomization and follow-up [39]
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A subgroup analysis of the 24 patients with complete 
data set with respect to:  Btotal,  ISIcomp, DI, HOMA-IR, 
 MCRikg/total and HEXi confirmed the results outlined 
previously. However, regarding  MCRikg the effects of 
liraglutide and placebo were comparable to the analysis 
based on all patients, nevertheless, the placebo corrected 
difference reached statistical significance (p = 0.03).
NEFA
Baseline fasting NEFA did not correlate to weight, BMI 
or HOMA-IR. AUC NEFA did not change significantly in 
the placebo period in contrast to the liraglutide period 
in which AUC NEFA increased significantly, but the dif-
ference between the groups was not statistical different 
(p = 0.13) (Table 3). The amount of insulin required to 
suppress NEFA production  (NEFAins) was not changed 
significantly in placebo period but was reduced in 
liraglutide period; − 470 (− 1790 to 10) nmol/pmol, 
p < 0.05 (Fig. 2).
Hba1c and body weight
HbA1c at 47 [6] mmol/mol was reduced by − 3.3 (6.51) 
mmol/mol, p < 0.01 and body weight at 93 (85 to 108) 
kg was reduced by − 2.7 (− 6.7 to − 0.6) kg, p = 0.0004, 
both corrected for placebo treatment.
Explanatory variables and carry‑over effect
We found no correlations between weight loss and 
 ISIcomp; placebo  (R2 = 0.01; p > 0.7) and liraglutide 
 (R2 = 0.06; p > 0.2) or weight loss and DI; placebo 
 (R2 < 0.01; p > 0.7) and liraglutide  (R2 = 0.08; p > 0.2). The 
variance of weight loss was not associated with base-
line weight, BMI, age, sequence of treatment, and dif-
ferences in treatment duration [39]. The presence of a 
possible carry-over effect was estimated using sum val-
ues by the t-test [40], but we did not find any significant 
carry-over effect between periods with respect to weight 
loss (p = 0.4) [39], DI (p = 0.4),  Btotal (p = 0.1) or  ISIcomp 
(p = 0.1).
Fig. 2 Plasma levels of glucose (a), C-peptide (b), insulin (c), insulin secretion rates (d), glucagon (e) and NEFA (f) during meal test
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Post‑hoc power calculation
Power calculation was based on improvement of dispo-
sition index during i.v. glucose test as reported earlier 
[39]. In the present paper we report secondary outcomes, 
and post-hos power analysis were done. Given a power 
of 80% and a level of significance of p < 0.05 we would be 
able to detect an increase in Disposition index on > 40% 
with n = 34 patients in paired analysis.  BTotal an increase 
on 20% with 28 patients, however, regarding  ISIComposite 
we would need n = 134 patient for detecting the same 
change in paired analysis.
Compliance and safety
Use of the study drugs (metformin, liraglutide and pla-
cebo) was counted, and compliance to liraglutide/placebo 
and metformin was > 90% of prescribed dosages with 
no significant differences between treatment periods. 
Adverse event frequency was higher in the active treat-
ment periods predominantly due to gastrointestinal side 
effects. Serious adverse events were observed in a total 
of 9 cases; 3 in the active period, 4 in the placebo period 
and 2 in the wash-out period. A detailed description of 
adverse events is published elsewhere [41].
Discussion
This meal test study of newly diagnosed well-controlled 
patients with T2DM and established CAD showed that 
liraglutide combined with metformin versus metformin 
(+placebo) significantly improved beta-cell function with 
a trend towards improved insulin sensitivity. Of note, the 
combination of the insulinotropic liraglutide and met-
formin reduced post-prandial insulin levels in face of a 
reduced glucose excursion, which is a new finding in this 
setting.
In this population we have already shown by use of an 
non-physiologic intravenous glucose tolerance test a sig-
nificant improvement in hyperglycemia and a significant 
increase in insulin levels [39], which was expected as lira-
glutide is an insulin secretagogue [12].
However, in the present study we report data from 
a mixed meal test where we observed a reduction of 
insulin as well as glucose levels during this physiologi-
cal test. The effect of liraglutide on beta-cell responsive-
ness  (Btotal) was neutral. These finding might in part be 
explained by the very well-controlled hyperglycemia with 
a mean HbA1c of 47  mmol/mol and a baseline fasting 
plasma glucose on 5.3 mmol/l. Despite these findings the 
improvement in disposition index is substantial in the 
present study, just as seen in the non-physiological set-
ting using intravenous glucose as beta-cell stimulation in 
combination with the so called “minimal model” in the 
same patients [39]. The novelty of the present physiologic 
study is that despite reduction of insulin levels, liraglu-
tide (combined to metformin) retains its strong effect on 
beta-cell function (i.e. disposition index) in patients with 
well-controlled T2D and established CAD.
Furthermore, the combination therapy improved 
insulin clearance and insulin sensitivity, both hepatic 
and peripheral. In our setup we evaluated basal level of 
hepatic insulin extraction but did not find effect of lira-
glutide on this, however basal level was reduced com-
pared to which was previously reported on glucose 
intolerant subjects [42]. Reduced hepatic extraction is the 
primary cause of high levels of circulating insulin after a 
glucose load [42] and in normoglycemic subjects hepatic 
extraction is suppressed up to 30% for ≤ 150 min follow-
ing a glucose load [38] and 40–50% of secreted insulin is 
extracted during a standard meal [38]. A body weight loss 
of > 10 kg increased hepatic extraction of insulin [43] and 
the weight loss in our study was only < 3 kg.
A recent Japanese study used a mixed meal test and 
compared metformin and liraglutide as monotherapy 
in patients with T2DM, and was able to demonstrate 
improvements in beta-cell function (measured as disposi-
tion index) by liraglutide compared to no effect following 
metformin therapy [44]. An earlier acute study of 11 sub-
jects with type 2 diabetes and with a HbA1c of 6.5 ± 0.6% 
Fig. 3 The hyperbolic relationship between  Btotal and  ISIComposite—
Open circles represents all pretreatment values, i.e. baseline values 
combined with values after wash-out before beginning of period 
2. The hyperbolic function is evident for both groups and for all 
pretreatment values. Fitted (all);  R2 = 0.81, fitted (baseline):R2 = 0.8, 
fitted (washout);  R2 = 0.83. Treatment effect is indicated by square 
and triangle (liraglutide vs. placebo), beginning and end of treatment 
are depicted by arrows
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a single dose of liraglutide revealed an increase in fast-
ing ISR but post meal AUC ISR was unaltered in contrast 
to AUC glucose which was markedly reduced, indicating an 
improved beta-cell function [45].
The effect on the alpha-cell function was unexpected; 
fasting glucagon levels increased during liraglutide and 
placebo treatments but neither treatment led to lower 
glucagon responses during meal test.
Data from the liraglutide effect and action in diabetes 
(LEAD) studies are conflicting with respect to the effect 
on fasting glucagon levels; in LEAD-3 a decrease of fast-
ing glucagon was found but no effect was observed in 
LEAD-4 [15, 17]. The absent suppression of glucagon 
in the present study may indicate a somewhat different 
action of liraglutide on alpha-cell function compared to 
native GLP-1, which may relate to the duration of treat-
ment, since a short term period of GLP-1-infusion inhib-
its glucagon secretion [46], whereas a long term infusion 
does not retain the same glucagon suppressive effect [20]. 
However, a previous study on patients with early stage 
T2DM revealed somewhat ambiguous results [47, 48], 
and it is suggested that attention must be paid to the per-
formance of the assay used to measure glucagon, in order 
to obtain valid results [29]. Additionally, the observed 
differences in glucagon response can to some extend be 
caused by differences in the composition of the test meals 
[49] and whether a the oral challenge is a mixed meal or 
glucose [50]. It is indicated that postprandial glucagon 
levels are increased after at mixed meal as compared to 
glucose alone [50]. We therefore speculate that the pre-
sent setting may implicate a somewhat different glucagon 
response compared to an oral glucose challenge or, alter-
natively that subjects with more advanced disease might 
reveal a different picture.
In T2DM the suppression of NEFA by insulin is dimin-
ished and increased NEFA levels impair insulin action 
and insulin secretion [1]. In the present study liraglu-
tide did not change suppression of NEFA compared with 
metformin but less insulin was needed to suppress post-
prandial NEFA in the liraglutide arm.
The present results suggest that in well-controlled sub-
jects with type 2 diabetes the positive effect of liraglutide 
treatment on beta-cell function is clinically relevant but 
the effect on alpha cell function is subtle. Additionally, 
the combination of liraglutide with metformin improves 
insulin sensitivity and clearance and no effect on post-
meal hepatic extraction of insulin. However, it is empha-
sized that liraglutide may produce another metabolic 
response in patients with less well-controlled and more 
advanced diabetes patients, which limits the generaliza-
tion of this study.
A limitation of the study was the relatively few sam-
ples and a short duration of the meal test, since longer 
protocols of longer duration including a higher number 
of samples will reveal a more detailed picture of early as 
well as late insulin secretion and alpha-cell function as 
well as NEFA metabolism in response to a meal test [51]. 
The disposition index calculated from the mixed meal 
test remains to be validated. The assumption is that the 
beta-cell adaption to ambient insulin resistance follows 
a hyperbolic law (y = 1/x), and that the product AIR glu-
cose × Si (the disposition index), therefore, is constant in 
people with normal beta-cell function. The disposition 
index in subjects with type 2 diabetes is used to obtain 
a correct estimate of the beta-cell function it relation to 
the prevailing degree of insulin resistance of the indi-
vidual. In the present study we tested for the hyperbolic 
law in the basal state and found a  R2 = 0.81 suggesting 
that the disposition index may be valid. However, post 
hoc power analysis indicates that changes in some of the 
indices reported, especially regarding  ISIComposite could 
flawed due to the study being underpowered. Neverthe-
less, this explorative study could indicate a more meta-
bolic flexibility of liraglutide treatment than previously 
acknowledged. The data presented her warrants further 
experiments in a greater population.
The data presented here were obtained during a rela-
tively short-term treatment period and demonstrated 
the effects of liraglutide in newly diagnosed patients. 
Data from real-world clinical practice indicates that the 
treatments effects we observed are similar to what was 
observed in clinical trials [52]. The present study aimed 
to reveal treatment effects on pathophysiological fea-
tures of early T2DM and CAD, yet we speculate that 
effects in more advanced disease might reveal a differ-
ent picture, which might add to our knowledge behind 
the long term positive cardiovascular profile of liraglu-
tide [53]. In accordance with clinical trails the side-effect 
profile of liraglutide was relatively low and comprised 
mainly of gastrointestinal events, which often resolves 
within 4 weeks of therapy [41, 54]. The present study did 
not indicate pathophysiological pathways, which could 
indicate possible adverse long-term effects. Adverse out-
come in our trial does not differ substantially from clini-
cal trials [41, 54]. Additionally, recent data indicates that 
liraglutide treatment is not associated with an increased 
risk for pancreatitis or pancreatic cancer [55].
Conclusions
In patients with well-controlled T2DM and CAD liraglu-
tide treatment significantly improved disposition index 
as a measure of beta-cell function but has no effect on 
alpha-cell function. Combined with metformin, liraglu-
tide reduced ambient insulin levels and improved insulin 
sensitivity and insulin clearance in a physiologic meal test 
Page 11 of 12Anholm et al. Diabetol Metab Syndr           (2019) 11:42 
setting suggesting that liraglutide is as a flexible insulino-
tropic drug in these patients.
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